Skip to main content
SpringerLink
Log in

Bone Diseases and Dental Implant Treatment

  • Chapter
  • First Online:
Dental Implant Treatment in Medically Compromised Patients

Abstract

Bone diseases, which mainly affect whole-body skeleton, also influence the metabolism, turnover, and remodeling of cranial and maxillofacial bone, resulting in unnormal bone volume, bone mineral density, biomechanical strength, and osseo-healing of mandible as well as maxillary. Thus, bone diseases influence dental implant treatment. Here, we introduce related bone diseases and treatment suggestions for these patients. Moreover, as one of the most important treatments for these diseases, antiresorptive and antiangiogenic drugs are usually used in these cases. However, these two treatments might result in MRONJ. So, we also introduce the incident, cautions for MRONJ, and dental implant treatment in this part. Following these suggestions might minimalize the risk of developing related complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Otomo-Corgel J. Osteoporosis and osteopenia: implications for periodontal and implant therapy. Periodontol. 2012;59:111–28.

    Article  Google Scholar 

  2. Saggese G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention. J Pediatr Endocrinol Metab. 2001;14:833–26.

    Article  PubMed  Google Scholar 

  3. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254–8.

    Article  PubMed  Google Scholar 

  4. Kyrgidis A, Tzellos TG, Toulis K, Antoniades K. The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complications. J Osteoporos. 2011;2011:147689.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Law AN, Bollen AM, Chen SK. Detecting osteoporosis using dental radiographs: a comparison of four methods. J Am Dent Assoc. 1996;127:1734–8.

    Article  PubMed  Google Scholar 

  6. Drozdzowska B, Pluskiewicz W, Tarnawska B. Panoramic-based mandibular indices in relation to mandibular bone mineral density and skeletal status assessed by dual energy X-ray absorptiometry and quantitative ultrasound. Dentomaxillofac Radiol. 2002;31:361–7.

    Article  PubMed  Google Scholar 

  7. Jonasson G, Alstad T, Vahedi F, Bosaeus I, Lissner L, Hakeberg M. Trabecular pattern in the mandible as bone fracture predictor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:e42–9.

    Article  PubMed  Google Scholar 

  8. Corcuera-Flores JR, Alonso-Dominguez AM, Serrera-Figallo MA, Torres-Lagares D, Castellanos-Cosano L, Machuca-Portillo G. Relationship between osteoporosis and marginal bone loss in osseointegrated implants: a 2-year retrospective study. J Periodontol. 2016;8:14–6.

    Article  Google Scholar 

  9. Jonasson G, Rythen M. Alveolar bone loss in osteoporosis: a loaded and cellular affair? Clin Cosmet Investig Dent. 2016;8:95–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Al-Ekrish AA, Widmann G, Alfadda SA. Revised, computed tomography-based Lekholm and Zarb jawbone quality classification. Int J Prosthodont. 2018;31:342–5.

    Article  PubMed  Google Scholar 

  11. Devlin H, Ferguson MW. Alveolar ridge resorption and mandibular atrophy. A review of the role of local and systemic factors. Br Dent J. 1991;170:101–4.

    Article  PubMed  Google Scholar 

  12. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc. 1996;127:370–7.

    Article  PubMed  Google Scholar 

  13. Krall EA, Dawson-Hughes B, Hannan MT, Wilson PW, Kiel DP. Postmenopausal estrogen replacement and tooth retention. Am J Med. 1997;102:536.

    Article  PubMed  Google Scholar 

  14. Makker A, Singh MM, Mishra G, Singh BP, Jain GK, Jadhav S. Relationship between bone turnover biomarkers, mandibular bone mineral density, and systemic skeletal bone mineral density in premenopausal and postmenopausal Indian women. Menopause. 2012;19:642–9.

    Article  PubMed  Google Scholar 

  15. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017;318:2466–22.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M, et al. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults. Rockville: An Evidence Review for the U.S. Preventive Services Task Force; 2018.

    Book  Google Scholar 

  17. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13:220–11.

    Article  PubMed  Google Scholar 

  18. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5:898–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiodt M, Klinge B. The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 2018;29(Suppl 18):54–18.

    Article  PubMed  Google Scholar 

  20. Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015;11:461–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Blake GM, Fogelman I. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy. Clin Interv Aging. 2006;1:367–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Devogelaer JP, Boutsen Y, Manicourt DH. Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men. Curr Osteoporos Rep. 2010;8:154–7.

    Article  PubMed  Google Scholar 

  23. Langdahl BL, Ljunggren O, Benhamou CL, Marin F, Kapetanos G, Kocjan T, et al. Fracture rate, quality of life and Back pain in patients with Osteoporosis treated with Teriparatide: 24-month results from the extended Forsteo observational study (ExFOS). Calcif Tissue Int. 2016;99:259–12.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mombelli A, Cionca N. Systemic diseases affecting osseointegration therapy. Clin Oral Implants Res. 2006;17(Suppl 2):97–6.

    Article  PubMed  Google Scholar 

  25. de Medeiros F, Kudo GAH, Leme BG, Saraiva PP, Verri FR, Honorio HM, et al. Dental implants in patients with osteoporosis: a systematic review with meta-analysis. Int J Oral Maxillofac Surg. 2018;47:480–11.

    Article  PubMed  Google Scholar 

  26. Merheb J, Temmerman A, Rasmusson L, Kubler A, Thor A, Quirynen M. Influence of skeletal and local bone density on dental implant stability in patients with Osteoporosis. Clin Implant Dent Relat Res. 2016;18:253–7.

    Article  PubMed  Google Scholar 

  27. Temmerman A, Rasmusson L, Kubler A, Thor A, Quirynen M. An open, prospective, non-randomized, controlled, multicentre study to evaluate the clinical outcome of implant treatment in women over 60 years of age with osteoporosis/osteopenia: 1-year results. Clin Oral Implants Res. 2017;28:95–7.

    Article  PubMed  Google Scholar 

  28. Galindo-Moreno P, Leon-Cano A, Ortega-Oller I, Monje A, F OV, Catena A. Marginal bone loss as success criterion in implant dentistry: beyond 2 mm. Clin Oral Implants Res. 2015;26:e28–6.

    Article  PubMed  Google Scholar 

  29. Wagner F, Schuder K, Hof M, Heuberer S, Seemann R, Dvorak G. Does osteoporosis influence the marginal peri-implant bone level in female patients? A cross-sectional study in a matched collective. Clin Implant Dent Relat Res. 2017;19:616–7.

    Article  PubMed  Google Scholar 

  30. Dvorak G, Arnhart C, Heuberer S, Huber CD, Watzek G, Gruber R. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study. J Clin Periodontol. 2011;38:950–5.

    Article  PubMed  Google Scholar 

  31. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349–4.

    PubMed  Google Scholar 

  32. Moy PK, Medina D, Shetty V, Aghaloo TL. Dental implant failure rates and associated risk factors. Int J Oral Maxillofac Implants. 2005;20:569–8.

    PubMed  Google Scholar 

  33. August M, Chung K, Chang Y, Glowacki J. Influence of estrogen status on endosseous implant osseointegration. J Oral Maxillofac Surg. 2001;59:1285–9.

    Article  PubMed  Google Scholar 

  34. Singhal S, Chand P, Singh BP, Singh SV, Rao J, Shankar R, et al. The effect of osteoporosis on residual ridge resorption and masticatory performance in denture wearers. Gerodontology. 2012;29:e1059–7.

    Article  PubMed  Google Scholar 

  35. Grocholewicz K, Bohatyrewicz A. Oral health and bone mineral density in postmenopausal women. Arch Oral Biol. 2012;57:245–7.

    Article  PubMed  Google Scholar 

  36. Jabbar S, Drury J, Fordham J, Datta HK, Francis RM, Tuck SP. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. J Periodontal Res. 2011;46:97.

    Article  PubMed  Google Scholar 

  37. Reinhardt RA, Payne JB, Maze CA, Patil KD, Gallagher SJ, Mattson JS. Influence of estrogen and osteopenia/osteoporosis on clinical periodontitis in postmenopausal women. J Periodontol. 1999;70:823–8.

    Article  PubMed  Google Scholar 

  38. Payne JB, Stoner JA, Nummikoski PV, Reinhardt RA, Goren AD, Wolff MS, et al. Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women. J Clin Periodontol. 2007;34:776–11.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Horner K, O’Malley L, Taylor K, Glenny AM. Guidelines for clinical use of CBCT: a review. Dentomaxillofac Radiol. 2015;44:20140225.

    Article  PubMed  Google Scholar 

  40. Subramaniam P, Gupta M, Mehta A. Oral health status in children with renal disorders. J Clin Pediatr Dent. 2012;37:89–4.

    Article  PubMed  Google Scholar 

  41. Tsolaki IN, Madianos PN, Vrotsos JA. Outcomes of dental implants in osteoporotic patients. A literature review. J Prosthodont. 2009;18:309–14.

    Article  PubMed  Google Scholar 

  42. Herrero-Climent M, Albertini M, Rios-Santos JV, Lazaro-Calvo P, Fernandez-Palacin A, Bullon P. Resonance frequency analysis-reliability in third generation instruments: Osstell mentor(R). Med Oral Patol Oral Cir Bucal. 2012;17:e801–6.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Chrcanovic BR, Albrektsson T, Wennerberg A. Smoking and dental implants: a systematic review and meta-analysis. J Dent. 2015;43:487–9.

    Article  PubMed  Google Scholar 

  44. Chrcanovic BR, Kisch J, Albrektsson T, Wennerberg A. Factors influencing early dental implant failures. J Dent Res. 2016;95:995–7.

    Article  PubMed  Google Scholar 

  45. Smeets R, Henningsen A, Jung O, Heiland M, Hammacher C, Stein JM. Definition, etiology, prevention and treatment of peri-implantitis—a review. Head Face Med. 2014;10:34.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.

    Article  PubMed  Google Scholar 

  47. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253–4.

    Article  PubMed  Google Scholar 

  48. Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent. 2014;2014:192320.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901–3.

    Article  PubMed  Google Scholar 

  50. Fleisch H, Russell RG, Bisaz S, Casey PA, Muhlbauer RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res. 1968;Suppl:10–10a.

    Article  Google Scholar 

  51. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–15.

    Article  PubMed  Google Scholar 

  52. Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH. Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev. 2017;12:CD004956.

    PubMed  Google Scholar 

  53. Ou YJ, Chiu HF, Wong YH, Yang YH. Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2016;25:1107–15.

    Article  PubMed  Google Scholar 

  54. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(Suppl 4):28–9.

    Article  PubMed  Google Scholar 

  55. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35:87–12.

    Article  PubMed  Google Scholar 

  56. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 2003;21:3150–7.

    Article  PubMed  Google Scholar 

  57. Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf. 2003;26:661–20.

    Article  PubMed  Google Scholar 

  58. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42:175–20.

    Article  PubMed  Google Scholar 

  59. Tanko LB, McClung MR, Schimmer RC, Mahoney P, Christiansen C. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone. 2003;32:421–6.

    Article  PubMed  Google Scholar 

  60. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–13.

    Article  PubMed  Google Scholar 

  61. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12:1358–9.

    Article  PubMed  Google Scholar 

  62. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003;33:805–11.

    Article  PubMed  Google Scholar 

  63. Katsuki H, Bloch K. Studies on the biosynthesis of ergosterol in yeast. Formation of methylated intermediates. J Biol Chem. 1967;242:222–7.

    PubMed  Google Scholar 

  64. Lynen F. Biosynthetic pathways from acetate to natural products. Pure Appl Chem. 1967;14:137–10.

    Article  PubMed  Google Scholar 

  65. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163–8.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235–7.

    PubMed  Google Scholar 

  67. Monkkonen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsalainen J, et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol. 2006;147:437–8.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res. 1998;13:1668–10.

    Article  PubMed  Google Scholar 

  69. Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Monkkonen J, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int. 2002;70:40–7.

    Article  PubMed  Google Scholar 

  70. McClung MR. Bisphosphonates. Endocrinol Metab Clin N Am. 2003;32(1):253–18.

    Article  Google Scholar 

  71. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938.

    Article  PubMed  Google Scholar 

  72. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws AAoO, Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–7.

    Article  Google Scholar 

  73. Mupparapu M. Editorial: medication-related osteonecrosis of the jaw (MRONJ): bisphosphonates, antiresorptives, and antiangiogenic agents. What next? Quintessence Int. 2016;47:7–8.

    PubMed  Google Scholar 

  74. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3–20.

    Article  PubMed  Google Scholar 

  75. Kalra S, Jain V. Dental complications and management of patients on bisphosphonate therapy: a review article. J Oral Biol Craniofac Res. 2013;3:25.

    Article  PubMed  Google Scholar 

  76. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl):233–14.

    Article  PubMed  Google Scholar 

  77. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218:62–79.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interf Cytokine Res. 2005;25:144–7.

    Article  Google Scholar 

  79. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893–4.

    PubMed  Google Scholar 

  80. Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:234.

    Article  PubMed  Google Scholar 

  81. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155.

    Article  PubMed  Google Scholar 

  82. Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry SM, et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res. 2013;28:1631–9.

    Article  PubMed  Google Scholar 

  83. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res. 2012;27:2130–13.

    Article  PubMed  Google Scholar 

  84. Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, et al. Sinus tracts—an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009;67:593–8.

    Article  PubMed  Google Scholar 

  85. Listed N. Osteoporosis medications and your dental health. J Am Dent Assoc. 2011;142:1320.

    Article  Google Scholar 

  86. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7:1823–9.

    Article  PubMed  Google Scholar 

  87. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009;116:433–9.

    Article  PubMed  Google Scholar 

  88. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403–10.

    Article  PubMed  Google Scholar 

  89. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181–8.

    Article  PubMed  Google Scholar 

  90. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012;107:1665–6.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Koch FP, Walter C, Hansen T, Jager E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Max Surg. 2011;15:63–6.

    Article  Google Scholar 

  92. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:e1–3.

    Article  PubMed  Google Scholar 

  93. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243–10.

    Article  PubMed  Google Scholar 

  94. Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2012;30:171–11.

    Article  PubMed  Google Scholar 

  95. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010;141:1365.

    Article  PubMed  Google Scholar 

  96. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27:243–11.

    Article  PubMed  Google Scholar 

  97. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–7.

    Article  PubMed  Google Scholar 

  98. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67:1167–6.

    Article  PubMed  Google Scholar 

  99. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012;41:1397–6.

    Article  PubMed  Google Scholar 

  100. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012;48:817–21.

    Article  PubMed  Google Scholar 

  101. Scoletta M, Arata V, Arduino PG, Lerda E, Chiecchio A, Gallesio G, et al. Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg. 2013;71:994–9.

    Article  PubMed  Google Scholar 

  102. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.

    Article  PubMed  Google Scholar 

  103. Tsao C, Darby I, Ebeling PR, Walsh K, O’Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71:1360–6.

    Article  PubMed  Google Scholar 

  104. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2–12.

    PubMed  Google Scholar 

  105. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634–8.

    Article  PubMed  Google Scholar 

  106. Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 1937;2014(72):e1–8.

    Google Scholar 

  107. Tallarico M, Canullo L, Xhanari E, Meloni SM. Dental implants treatment outcomes in patient under active therapy with alendronate: 3-year follow-up results of a multicenter prospective observational study. Clin Oral Implants Res. 2016;27:943–9.

    Article  PubMed  Google Scholar 

  108. Ata-Ali J, Ata-Ali F, Penarrocha-Oltra D, Galindo-Moreno P. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res. 2016;27:e38.

    Article  PubMed  Google Scholar 

  109. Walter C, Al-Nawas B, Wolff T, Schiegnitz E, Grotz KA. Dental implants in patients treated with antiresorptive medication - a systematic literature review. Int J Implant Dent. 2016;2:9.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent. 2013;61:33–8.

    PubMed  Google Scholar 

  111. Rasmussen JM, Hopfensperger ML. Placement and restoration of dental implants in a patient with Paget’s disease in remission: literature review and clinical report. J Prosthodont. 2010;17:35.

    Google Scholar 

  112. Gomez-De Diego R, Mang-Del RM, Romero-Perez M, et al. Indications and contraindications of dental implants in medically compromised patients: Update. Med Oral Patol Oral. 2014:e483–6.

    Google Scholar 

  113. Lalam R, Cassar-Pullicino V, Winn N. Paget disease of bone. Semin Musculoskel R. 2016;20:287–12.

    Article  Google Scholar 

  114. Valenzuela EN, Pietschmann P. Epidemiology and pathology of Paget’s disease of bone—a review. Wien Med Wochenschr. 2017;167:2–6.

    Article  Google Scholar 

  115. Al-Rashid M, Ramkumar DB, Raskin K, Schwab J, Hornicek FJ. Paget disease of bone. Orthop Clin North Am. 2015;46:577–8.

    Article  PubMed  Google Scholar 

  116. Torres J, Tamimi F, Garcia I, Herrero A, Rivera B, Sobrino JA. Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report. Oral Surg Oral Med O. 2009;107:387–5.

    Article  Google Scholar 

  117. Fenerty S, Shaw W, Verma R, Syed AB, Kuklani R, Yang J, et al. Florid cemento-osseous dysplasia: review of an uncommon fibro-osseous lesion of the jaw with important clinical implications. Skelet Radiol. 2017;46:581–9.

    Article  Google Scholar 

  118. Miyake M. Nagahata SJIJoO, Surgery M. Florid cemento-osseous dysplasia. Report of a case. Int J Oral Maxillofac Surg. 2010;28:56–7.

    Article  Google Scholar 

  119. Grün P, Bandura P, Grün A, Sutter W, Meller O, Turhani D. Sensory disturbance along the inferior alveolar nerve as a first clinical sign of multiple florid cemento-osseous dysplasia of the mandible—a case report. Int J Surg Case Rep. 2018;53:452–7.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Eren Y, Serdar B, Ertugrul CM, Erdal OJJO, Jomfp MP. Florid cemento-osseous dysplasia: a rare case report evaluated with cone-beam computed tomography. J Oral Maxillofac Surg. 2016;20:329.

    Google Scholar 

  121. Esfahanizadeh N, Yousefi H. Successful implant placement in a case of florid Cemento-osseous dysplasia: a case report and literature review. J Oral Implant. 2018;44:275–9.

    Article  Google Scholar 

  122. Gerlach RC, Dixon DR, Goksel T, Castle JT, Henry W. Case presentation of florid cemento-osseous dysplasia with concomitant cemento-ossifying fibroma discovered during implant explantation. Med Oral Patol Oral. 2013;115:e44–8.

    Google Scholar 

  123. Consolaro A, Paschoal S, Ponce JB, Miranda D, Consolaro A, Paschoal S, et al. Florid cemento-osseous dysplasia: a contraindication to orthodontic treatment in compromised areas. Dent Press J Ortho. 2018;23:26–8.

    Article  Google Scholar 

  124. Nthumba PM. Osteosarcoma of the jaws: a review of literature and a case report on synchronous multicentric osteosarcomas. World J Surg Onco. 2012;10:240.

    Article  Google Scholar 

  125. Gurlek A, Miller M, Jacob RF, Lively J, Schusterman MJP, Surgery R. Functional results of dental restoration with osseointegrated implants after mandible reconstruction. Plastic Recons Surg. 1998;101:650–5.

    Article  Google Scholar 

  126. Albrektsson T, Zarb G, Worthington P, Eriksson AR. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986;1:11.

    PubMed  Google Scholar 

  127. Arvidson K, Bystedt H, Frykholm A, Konow LV, Lothigius EJCOIR. Five-year prospective follow-up report of the astra tech dental implant system in the treatment of edentulous mandibles. Clin Oral Imolan Res. 2010;9:225–9.

    Article  Google Scholar 

  128. Buser D, Mericske-Stern R, Bernard JP, Behneke A, Behneke N, Hirt HP, et al. Long-term evaluation of non-submerged ITI implants. Part 1: 8-year life table analysis of a prospective multi-center study with 2359 implants. Clin Oral Implants Res. 2010;8:161–11.

    Article  Google Scholar 

  129. Garrett N, Roumanas ED, Blackwell KE, Freymiller E, Abemayor E, Weng KW, et al. Efficacy of conventional and implant-supported mandibular resection prostheses: study overview and treatment outcomes. J Prosthet Dent. 2006;96:13–1.

    Article  PubMed  Google Scholar 

  130. Hotz G. Reconstruction of mandibular discontinuity defects with delayed nonvascularized free iliac crest bone grafts and endosseous implants: a clinical report. J Prosthet Dent. 1996;76:350.

    Article  PubMed  Google Scholar 

  131. Chiapasco M, Romeo E, Vogel G. Vertical distraction osteogenesis of edentulous ridges for improvement of oral implant positioning: a clinical report of preliminary results. Int J Oral Maxillofac Implants. 2001;16:43–8.

    PubMed  Google Scholar 

  132. Brauner E, Cassoni A, Battisti A, et al. Prosthetic rehabilitation in post-oncological patients: report of two cases. Advanced information systems engineering. Berlin, Heidelberg: Springer; 2010.

    Google Scholar 

  133. Rohner D, Bucher P, Kunz C, et al. Treatment of severe atrophy of the maxilla with the prefabricated free vascularized fibula flap. Clin Oral Implants Res. 2010;13:44–8.

    Article  Google Scholar 

  134. Snauwaert K, Duyck J, Steenberghe DV, et al. Time dependent failure rate and marginal bone loss of implant supported prostheses: a 15-year follow-up study. Clin Oral Investig. 2000;4:13–7.

    Article  PubMed  Google Scholar 

  135. Hutchison IL, Dawood A, Tanner S. Immediate implant supported bridgework simultaneous with jaw reconstruction for a patient with mandibular osteosarcoma. Br Dent J. 2009;206:143.

    Article  PubMed  Google Scholar 

  136. Brauner E, Quarato A, Angelis FD, et al. Prosthetic rehabilitation involving the use of implants following a fibula free flap reconstruction in the treatment of osteosarcoma of the maxilla: a case report. Clin Ter. 2017;168:e392–4.

    PubMed  Google Scholar 

  137. Brauner E, Valentini V, Jamshir S, et al. Two clinical cases of prosthetical rehabilitation after a tumor of the upper maxilla. Europ R Med Pharm Sci. 2012;16:1882–8.

    Google Scholar 

  138. Pagnoni M, Amodeo G, Fadda MT, et al. Juvenile idiopathic/rheumatoid arthritis and orthognatic surgery without mandibular osteotomies in the remittent phase. J Craniomaxillofac Surg. 2013;24:1940–5.

    Article  Google Scholar 

  139. Edoardo B, Giorgio P, Alessandro Q, et al. Maxillofacial prosthesis in dentofacial traumas: a retrospective clinical study and introduction of new classification method. Biomed Res Int. 2017;2017:1–7.

    Google Scholar 

  140. De AF, Papi P, Mencio F, et al. Implant survival and success rates in patients with risk factors: results from a long-term retrospective study with a 10 to 18 years follow-up. Euro R Med Pharm Sci. 2017;21:433.

    Google Scholar 

  141. Sieg P, Hasse A, Zimmermann CE. Versatility of vascularized fibula and soft tissue graft in the reconstruction of the mandibulofacial region. Int J Oral Maxillofac Surg. 2010;28:356–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China

    Yu-chen Guo & Quan Yuan

  2. Department of Oral Implantology, West China Hospital of Stomatology, Sichuan University, Chengdu, China

    Quan Yuan

Authors
  1. Yu-chen Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quan Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quan Yuan .

Editor information

Editors and Affiliations

  1. West China School of Stomatology, Sichuan University, Chengdu, China

    Quan Yuan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Guo, Yc., Yuan, Q. (2020). Bone Diseases and Dental Implant Treatment. In: Yuan, Q. (eds) Dental Implant Treatment in Medically Compromised Patients. Springer, Cham. https://doi.org/10.1007/978-3-030-28557-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28557-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28556-2

  • Online ISBN: 978-3-030-28557-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation